Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

The contribution of molecular alterations in bone marrow mesenchymal stromal cells (BM-MSC) to the pathogenesis of acute myeloid leukemia (AML) is poorly understood. Thus we assessed genome-wide ...

Chronic lymphocytic leukemia (CLL) starts in bone marrow, the soft inner part of your bones. There are some key differences that set CLL apart from other types of leukemia, such as ALL (acute ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML ...